01. Doctor Overview
Dr. David P. Carbone is a medical oncologist who established and currently serves as the director of the James Thoracic Center at the Ohio State University Medical Center (OSUMC). Prior to joining the staff at Ohio State University in 2012, Dr. Carbone was on the faculty of the University of Texas Southwestern Medical Center for five years before being recruited to Nashville, Tennessee’s Vanderbilt University in 1996 where he was a professor of medicine, cell biology, and cancer biology, and director of the Thoracic/Head and Neck Cancer Program. During his time at Vanderbilt, he also held the titles of director and principal investigator of the Vanderbilt Specialized Program of Research Excellence (SPORE) in Lung Cancer and principal investigator of the Strategic Partnering to Evaluate Cancer Signatures (SPECS) in Lung Cancer UO1 consortium.
Dr. Carbone’s clinical specialty is lung cancer, and in his role as director of the James Thoracic Center, he works towards cultivating collaborations amongst physicians and scientists in an effort to develop and bring to the forefront of patient care novel and targeted therapies for treating and curing lung cancer. In his more than 25 year career in the field of oncology, Dr. Carbone has always kept his focus on the discovery of cutting-edge lung cancer treatments. Of lung cancer, Dr. Carbone states: “This is a disease with unacceptable outcomes, but there are many promising therapies today and on the horizon.”
A noted researcher, Dr. Carbone has authored over 200 peer-reviewed publications, books, and review articles and currently serves as president of the International Association for the Study of Lung Cancer (IASLC). Dr. Carbone has received continuous National Cancer Institute (NCI) funding for his research endeavors since the onset of his career and has served on the Board of Scientific Counselors for the NCI, as well as on several NCI grant review panels. He is chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group (ECOG) and has served as either a co-principal investigator (PI) or Lab PI in as many as eight past or currently active ECOG trials.
02. Fast Facts
Doctor Fast Facts
Main Speciality: Medical Oncology
Other Interests & Specialties: Lung cancers, mesothelioma, carcinoma, non-small cell lung, small cell lung carcinoma, molecular genetics of lung tumors, cell biology and cancer biology.
Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Internal Medicine, Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group (ECOG), President of the International Association for the Study of Lung Cancer (IASLC), member of the Lung Cancer Expert Medical Advisory Panel for the American Lung Association, Barbara J. Bonner Chair in Lung Research
Education & Experience:
- Medical Degree from Johns Hopkins University School of Medicine
- Ph.D. in Molecular Biology and Genetics from Johns Hopkins University
- Residency in Internal Medicine at Johns Hopkins University
- Fellowship in Medical Oncology at the National Cancer Institute
- Internship in Internal Medicine at Johns Hopkins Hospital
Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. Journal of the National Cancer Institute. August 2000;92(16):1355-1357.
Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines. Cancer Research. September 1994;54(18):4988-92.
The effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibition in non-small cell lung cancer. Journal of Thoracic Oncology. February 2019;S1556-0864(19):30150-30159. doi: 10.1016/j.jtho.2019.02.019
Novel mechanism of resistance to targeted therapies in lung cancer. Molecular & Cellular Oncology. December 2018;6(1):1551015. doi: 10.1080/23723556.2018.1551015
Co-Expression Analysis Reveals Mechanisms Underlying the Varied Roles of NOTCH1 in NSCLC. Journal of Thoracic Oncology. February 2019;14(2):223-236. doi: 10.1016/j.jtho.2018.10.162